CELZ (Creative Medical Technology Holdings Inc.) stock: $0.62, $4.7M market cap, $6.8M cash, -$2.1M EV, $9.6M fully diluted market cap. Next expected readout: Jan-27. Lead program: CELZ-201-DDT (Chronic Low-back Pain), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
We are a commercial stage biotechnology company dedicated to the advancement regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following: Our subsidiary, Creative Medical Technologies, Inc.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Chronic lower back pain due to degenerative disc disease(Phase 2)
New onset Type 1 diabetes(Phase 2)
Status note Two FDA-cleared Phase 1/2 trials in progress: ADAPT (Olastrocel) for chronic lower back pain due to degenerative disc disease, a randomized Phase 1/2 study with FDA Fast Track designation; CREATE 1 for new onset Type 1 diabetes. Near-term priorities include completing ADAPT expanded-cohort enrollment and Phase 3 planning interactions.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Burn Pit Exposure; Airborne Hazard Exposure; Veteran Health
—
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.